Industry Insights
The Volatility of Rebate Management
The Volatility of Rebate Management Rebates Changing Due to Regulatory Pressure and Evolving Drug Market Why does the model need to change? The PBM market is in a state of tremendous fluctuation. We have:payors looking to decouple pharmacy benefit management services (e.g. use of non-verticallyintegrated big 3 PBM models and using claims processing, mail service, etc…
Read MoreOBESITY- Is The Treatment an Epidemic
OBESITY- Is The Treatment an Epidemic A white paper about the on & off-label use of the GLP-1 Agonists What is happening with the treatment of obesity? In this white paper, we will dive into the GLP-1 receptor agonists (“GLP-1”) for the treatment of obesity. Although GLP-1s have been used primarily for diabetes, we are…
Read MoreMedical or Pharmacy Benefit
Medical or Pharmacy Benefit A white paper on the background of pharmacy vs medical coverage Managing drug spend on both benefits With the pipeline of medications and treatments being largely ultra-expensive medications overwhelmingly infused, injected or through more expansive treatment protocols like gene therapies – decisioning on where to cover these medications is now, more…
Read MoreCovid Testing – Does Free Equal Frivolous?
Covid Testing – Does Free Equal Frivolous? A white paper concerns of waste, and coverage change What is Changing, and When? The requirement by the federal government for commercial coverage of COVID-19 tests ends May 11, 2023. While some have stated concern over a potential inability to get the testing once it is no longer…
Read MoreSanofi Joins Lilly and Novo Nordisk to Cut Insulin Prices (Update)
Sanofi Joins Lilly and Novo Nordisk to Cut Insulin Prices (Update) A white paper on what this means to medication cost management What is the Update? Following suit of Lilly and Novo Nordisk, Sanofi announced price decreases and caps on their insulin products that would take effect at the beginning of next year. Price decreases…
Read MoreNetwork Audit – Results vs Remedies
Network Audit – Results vs Remedies A white paper on pharmacy audit & investigations Understanding your audit and investigative program – is it working for you? In many cases, we see our audit and investigative reports and check a box that our vendors are managing the network and preventing Fraud, Waste, and Abuse (FWA). Running…
Read MoreLilly and Novo Nordisk to cut insulin Prices
Lilly and Novo Nordisk to cut insulin Prices A white paper on what this means to medication cost management What was the change? Both Lilly and Novo Nordisk have announced that their companies will reduce the price of several branded insulin products by as much as 75%. Novo’s decision on March 14th followed closely after Eli…
Read MoreManufacturer Funding Changes & Challenges
Manufacturer Funding Changes & Challenges A white paper on the opposing thoughts on patient assistance What is happening in the world of manufacturer funding assistance? We previously wrote a white paper on the ups and downs of manufacturer funding assistance – read that article on our Industy Insights section of PayerAlly.com. Now, we are taking…
Read MoreGene Therapy – “Therapy” Not Medication
Gene Therapy – “Therapy” Not Medication A white paper on understanding gene therapy What is Gene Therapy? Gene therapy is all the BUZZ in conversations about medication cost control and yet it is not a medication. So what is gene therapy and what makes it different than the ‘medications’ of the past. Why should we…
Read MoreManufacturer Funding – The Ups & Downs
Manufacturer Funding – The Ups & Downs A white paper on manufacturer funding Why is manufacturer subsidized funding a ‘big deal’? There has been a great deal of commentary on manufacturer funding, and how plans are using the funding to do more to offset patient cost share amounts. In this white paper, we are going…
Read More